ProPharma Group Acquires Weinberg Group to Expand U.S. Pre-Approval and Preclinical Regulatory Services

On January 29, 2019, VCBeat (WeChat official account: vcbeat) learned that ProPharma Group, a portfolio company of Linden Capital Partners, announced the acquisition of the Weinberg Group, headquartered in Washington.

Founded in 1983, the Weinberg Group is dedicated to providing regulatory and compliance services with a focus on FDA consultation, leveraging scientific and regulatory strategies to offer biotechnology, medical device, and pharmaceutical consulting services, drug development pathways, and compliance solutions for companies of all sizes.

Through this acquisition, ProPharma Group will expand its service offerings to include U.S. pre-approval and preclinical regulatory services, effectively establishing end-to-end solutions for global clients. Matthew Weinberg, CEO of The Weinberg Group, stated, “The Weinberg Group and ProPharma Group operate in two distinct market segments. Integrating The Weinberg Group’s regulatory and compliance expertise into ProPharma Group enhances our ability to support clients in product development.”

ProPharma Group is a comprehensive global pharmaceutical services platform, currently employing more than 1,100 people across the United States, Canada, Europe, Japan, and Australia. Dawn Sherman, CEO of ProPharma Group, stated, “ProPharma Group now possesses comprehensive expertise in life sciences consulting, medical information, pharmacovigilance, and regulatory affairs, enabling us to serve clients worldwide.”

On July 16, 2018, ProPharma Group announced the acquisition of Xendo Holding BV (Xendo). Headquartered in the Netherlands, Xendo provides compliance consulting, engineering and technical support, regulatory affairs, and pharmacovigilance services to biopharmaceutical companies. This acquisition expanded ProPharma Group’s geographic footprint for compliance consulting services and added high-value regulatory affairs and pharmacovigilance capabilities.

Linden Capital Partners is a Chicago-based private equity firm focused on investing in the healthcare industry. Linden primarily invests in middle-market platforms in the areas of medical products, specialty distribution, pharmaceuticals, and services.

(Compiled by Zhang Yaping)